Premium
Cost‐effectiveness of grass allergen tablet (GRAZAX ® ) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective
Author(s) -
Bachert C.,
Vestenbæk U.,
Christensen J.,
Griffiths U. K.,
Poulsen P. B.
Publication year - 2007
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.2007.02706.x
Subject(s) - medicine , allergen , allergen immunotherapy , allergy , asthma , cost effectiveness , immunology , risk analysis (engineering)
Summary Background The prevalence of allergic rhinoconjunctivitis has increased dramatically. Seventeen million people in the United Kingdom, Germany, the Netherlands, Sweden, Denmark, Norway and Finland suffer from grass pollen induced allergic rhinitis. Symptomatic therapy with antihistamines and topical steroids is partially effective but allergen‐specific immunotherapy by injection or sublingual routes is superior. The grass allergen tablet (GRAZAX ® ) is a new allergen‐specific immunotherapy for home administration. Objective To assess the cost‐effectiveness of the grass allergen tablet compared with symptomatic medication in seven Northern European countries. Methods A prospective pharmacoeconomic analysis was carried out alongside a multinational clinical trial. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a 9‐year time horizon. The outcome measure was Quality Adjusted Life Years (QALYs). Results The grass allergen tablet was clinically superior to symptomatic treatment, producing statistically significant differences for all efficacy end‐points, including the number of QALYs gained – 0.976 vs. 0.947 QALYs gained. There was a significantly higher usage of the rescue medications loratadine and budesonide, and more hours missed from work (production loss), in the symptomatic treatment group. The cost per QALY gained in the grass allergen tablet group was similar in the seven countries (€12 930 to €18 263 for an annual cost of the grass allergen tablet of €1500). The analysis showed that the grass allergen tablet was cost‐effective for all countries for an annual treatment cost below €2200. Conclusion The pharmacoeconomic analysis illustrated that allergen‐specific immunotherapy with the grass allergen tablet is a cost‐effective intervention for the prevention of grass pollen induced rhinoconjunctivitis in Northern European countries, for a tablet price below €6. In Germany for example the price of the tablet is €2.95 corresponding to a yearly treatment cost of €358 – based on a 9‐year time horizon.